Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Biomarker Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Biomarkers for Myocardial Infarction and Chronic Heart Failure

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines when measurement of cardiac biomarkers (e.g., troponin, BNP/NT-proBNP) is covered or not covered for diagnosis and management of myocardial infarction and chronic heart failure for Oscar Health members, and outlines limitations by setting and test type.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerOscar Health
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument timing of symptom onset, troponin assay type, and serial troponin sampling (presentation and repeat 3–6 hours or per assay algorithm) to support medical necessity and claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤4Troponin tests allowed (72h)
    ≤4/yrBNP/NT-proBNP outpatient (per year)
    multipleBiomarkers not covered
    POC/outpatientOutpatient setting restriction
    99th%Troponin decision level
    96%Centers reporting troponin primary

    Coverage Criteria for Cardiac Biomarker Testing

    Medically Necessary Uses

    Covered when the following conditions are met

    Troponin for suspected MI: For individuals presenting with signs and symptoms of acute coronary syndrome, quantitative measurement of cardiac troponin (troponin T or I) for diagnosis of myocardial infarction meets criteria up to four times within the first 72 hours following initial presentation.<= 4 tests within 72 hours

    Outpatient facility must be capable of performing an adequate clinical MI evaluation.

    BNP/NT-proBNP uses: Measurement of BNP or NT-proBNP meets criteria for: (a) diagnosing heart failure in individuals presenting with dyspnea; or (b) establishing disease severity in individuals with chronic heart failure (up to four times per year in outpatient setting).<= 4 tests/year for chronic HF

    Not Medically Necessary / Not Covered Biomarkers

    Not covered for diagnosis/prognosis of MI

    Listed non-covered biomarkers: Measurement of AST/SGOT, CKMB, CK, CK isoenzymes, LD/LDH, myoglobin, copeptin, troponin C, C-reactive protein, H-FABP, and any other cardiac biomarkers not listed as covered does not meet criteria for diagnosis and/or prognosis of MI.

    Includes both older enzyme markers and other emerging biomarkers

    Setting and Test-Format Restrictions

    Setting restriction for outpatient testing: Measurement of cardiac biomarkers in an outpatient setting that is not capable of performing adequate clinical MI evaluation (e.g., independent lab or physician's office) does not meet criteria.

    Qualitative troponin testing in outpatient setting also does not meet criteria.

    Troponin-based MI diagnosis

    Covered when testing follows guideline-based use:

    Troponin for MI diagnosis: Use high-sensitivity troponin I or T for evaluating myocardial injury; diagnosis requires a rising/falling pattern and at least one value above the 99th percentile upper reference limit.99th percentile

    Serial sampling per guideline (presentation and repeat 3–6 hours or per assay-specific algorithm)

    BNP / NT-proBNP for heart failure diagnosis and prognosis

    Covered when used to diagnose or manage heart failure:

    Natriuretic peptide testing: Measurement of BNP or NT-proBNP is appropriate in patients presenting with dyspnea to help establish or exclude heart failure and for prognosis in chronic HF; consider serial measurements in management.age-adjusted thresholds for NT-proBNP (optimal value varies by age)

    Up to four tests per year allowed in outpatient setting for chronic HF

    sST2 as prognostic adjunct

    Covered as adjunctive prognostic testing:

    sST2 testing: sST2 (measured by validated assays such as the Presage assay) may be used adjunctively for prognostic risk stratification in chronic heart failure and in select settings (e.g., transplant surveillance), with study-reported cutpoints associated with increased risk (example: >36.3 ng/mL).study-specific cutpoints (e.g., 36.3 ng/mL)

    Assays and cutpoints vary by platform; Presage measuring range 3.1–200 ng/mL

    Limited / historical biomarkers

    Not routinely recommended or limited utility:

    CK-MB, H-FABP, copeptin: CK-MB, H-FABP, and copeptin have inferior or inconsistent performance compared with troponins for MI diagnosis; CK-MB may be used only when troponin assays are unavailable; copeptin and H-FABP are not encouraged for routine assessment.

    CK-MB less sensitive/specific than troponin; some early diagnostic utility reported but troponin preferred

    Diagnosis of acute MI (troponin‑based)

    Covered when criteria align with major society guidance for diagnosis of MI or HF

    MI diagnosis with troponin: Measure cardiac-specific troponin (I or T), preferably high-sensitivity assays; a diagnosis of acute MI requires a rising and/or falling pattern with at least one value above the 99th percentile URL.99th percentile

    Measure at presentation and 3–6 hours after symptom onset; additional sampling beyond 6 hours if initial troponins normal but clinical/ECG concern

    Use of BNP/NT‑proBNP in HF

    Covered when used to diagnose, exclude, or risk‑stratify heart failure per guideline recommendations

    Natriuretic peptides for HF: Measure BNP or NT-proBNP in patients presenting with dyspnea to support diagnosis or exclusion of heart failure, and use BNP/NT-proBNP for risk stratification and prognosis in chronic HF.assay-specific

    Predischarge natriuretic peptide level may be useful for postdischarge prognosis; evidence for routine serial testing to guide therapy is insufficient

    Emerging biomarkers (sST2, galectin‑3, GDF‑15, copeptin)

    Emerging biomarkers may provide additive prognostic information but are not established for routine management decisions

    sST2 and other emerging biomarkers: sST2 is identified as an emerging biomarker with prognostic association and advantages (less affected by BMI, age, renal function); other biomarkers (galectin-3, GDF-15, copeptin) show prognostic value but lack consistent evidence to support routine management changes.none

    Guidelines acknowledge promise but stop short of recommending routine use for management guidance

    SCAI periprocedural MI criteria

    Periprocedural MI definitions after revascularization

    Post‑revascularization biomarker thresholds (SCAI): SCAI defines clinically relevant MI after PCI/CABG using CK‑MB or cTn absolute/relative increases (examples: CK‑MB peak >10x ULN or cTn rise >70x ULN within 48 hours in certain contexts) and associated clinical/ECG criteria.CK‑MB and cTn multiples of local ULN as specified

    SCAI prefers CK‑MB but includes cTn if CK‑MB unavailable; applies to post‑procedural MI definitions

    Guideline recommendations for biomarker use

    Guideline-based recommendations for use of troponin and natriuretic peptides

    hs-cTn preferred biomarker: Cardiac troponin (I or T), preferably high-sensitivity assays, should be utilized to detect or exclude myocardial injury.

    hs-cTn assays have greater sensitivity and negative predictive value and are preferred for routine use

    Sampling interval: Obtain an initial troponin sample at assessment and, when obtaining multiple samples, take a second sample 30 minutes to 3 hours after the first (or per assay-specific algorithm).30-180 minutes

    NICE recommends 30 min–3 hr interval; ACC/AHA recommends presentation and 3–6 hr repeat as appropriate

    Threshold selection: Use 99th percentile thresholds or thresholds at/near the limit of detection of the assay; an initial positive result near the limit of detection should not be used to rule in NSTEMI.99th percentile or near LOD

    Measurement of any cardiac biomarkers not listed as covered (for example, copeptin, troponin C, C‑reactive protein, H‑FABP, and other nonlisted markers) does not meet criteria due to lack of sufficient published evidence that these tests are required or beneficial for diagnosis or prognosis of myocardial infarction.

    Older biomarkers such as CK‑MB and myoglobin are not recommended for routine diagnosis of acute coronary syndrome when cardiac troponin (cTn I or T) assays are available; troponin is the preferred primary biomarker. When a cTn assay is unavailable, CK‑MB may be used as an alternative, consistent with guidance that regards CK‑MB as less sensitive and specific than troponin.

    Professional guidance from the American Society for Clinical Pathology and AHA/ACC explicitly recommends against use of CK‑MB or myoglobin to diagnose acute myocardial infarction and advises that troponin I or T should be used instead; CK‑MB is considered acceptable only in settings where troponin assays are not available.

    NICE evaluated point‑of‑care options and noted that the diagnostic accuracy of the TriageTrue test when used on whole blood is uncertain. NICE therefore implies this test should be used cautiously and interpreted in the context of assay‑specific performance characteristics.

    ASCP guidance and cited evidence discourage testing for myoglobin or CK‑MB to diagnose acute myocardial infarction. These recommendations are referenced in the policy's evidence base and support avoidance of these older markers for primary AMI diagnosis.

    Qualitative (point‑of‑care) measurement of cardiac troponin in the outpatient setting does not meet criteria. The policy restricts use of qualitative troponin formats and measurement of older biomarkers (eg, CK‑MB, myoglobin) for diagnosis/prognosis of MI in outpatient settings that cannot perform an adequate clinical MI evaluation.

    Routine or standalone use of H‑FABP or copeptin for myocardial infarction assessment is not encouraged because troponin assays are generally superior; therefore, point estimates using H‑FABP or copeptin as sole diagnostics do not meet criteria for routine clinical MI evaluation.

    Guideline authors note that, although natriuretic peptides (BNP and NT‑proBNP) are useful to establish or exclude heart failure and for prognostic assessment, current evidence is insufficient to support natriuretic peptide‑guided therapy or specific serial BNP/NT‑proBNP measurement intervals to improve mortality or hospitalization outcomes; serial testing for treatment guidance is therefore not supported as standard of care.

    Procedure and Test Codes

    Recommended hs‑cTn assays (NICE list)mixed
    Access High‑Sensitivity Troponin I AssayAssay name recommended by NICE (example list of hs‑cTn assays)
    ADVIA Centaur High‑Sensitivity Cardiac Troponin‑I AssayAssay name recommended by NICE
    Alinity High Sensitive Troponin‑I assayAssay name recommended by NICE
    ARCHITECT STAT High Sensitive Troponin‑I assayAssay name recommended by NICE
    Atellica IM High‑Sensitivity Cardiac Troponin I AssayAssay name recommended by NICE
    Dimension Vista High‑Sensitivity Cardiac Troponin I AssayAssay name recommended by NICE
    Dimension EXL High‑Sensitivity Cardiac Troponin I AssayAssay name recommended by NICE
    Elecsys Troponin T‑high sensitive assayAssay name recommended by NICE
    Elecsys Troponin T‑high sensitive STAT assayAssay name recommended by NICE
    VIDAS High sensitive Troponin I assayAssay name recommended by NICE
    1–10 of 11
    1/2
    Referenced Procedure CodesCPT
    82550Creatine kinase (CK), (CPK); total
    82552Creatine kinase (CK), (CPK); isoenzymes
    82553Creatine kinase (CK), (CPK); MB fraction only
    82554Creatine kinase (CK), (CPK); isoforms
    82725Fatty acids, nonesterified
    83615Lactate dehydrogenase (LD), (LDH)
    83625Lactate dehydrogenase (LD), (LDH); isoenzymes, separation and quantitation
    83874Myoglobin
    83880Natriuretic peptide
    84450Transferase; aspartate amino (AST) (SGOT)
    1–10 of 15
    1/2
    inv-23: Troponin decision level — greater than the 99th percentile of the upper reference limit
    Decision levelGreater than the 99th percentile of the assay's upper reference limit (URL)
    RationaleAn acute MI is designated when a rising/falling troponin pattern is seen and at least one measurement is >99th percentile URL.
    Alternative when cTn unavailableCK‑MB decision level may be set at the 99th percentile of the URL per guidance.
    inv-24: Presage ST2 measuring range — 3.1 ng/mL to 200 ng/mL
    Measuring range (Presage ST2)3.1 ng/mL to 200 ng/mL
    Assay examplePresage® ST2 Assay (Critical Diagnostics) — FDA cleared for prognostic use in chronic HF

    Provider Responsibilities and Billing Guidance

    Prior Authorization

    Follow authorization & medical-necessity rules

    Policy states services must meet authorization and medical necessity guidelines; however, no specific prior authorization procedures or criteria are provided in the cited policy excerpts.

    Prior Authorization

    No PA statements in this section

    No prior authorization statements or provider-level PA steps are specified in the provided document sections.

    Prior Authorization

    No explicit PA; tests subject to medical‑necessity review

    The policy does not list explicit prior authorization requirements for biomarker testing in these excerpts; use of high-sensitivity troponin and natriuretic peptide testing is described as standard‑of‑care and subject to medical necessity review.

    Background and Evidence Summary

    Cardiac biomarkers are biochemical proteins and enzymes released into the bloodstream after myocardial injury and serve diagnostic and prognostic roles in both acute and chronic cardiovascular care. Troponin (I or T) is the recommended cardiac‑specific biomarker for detecting myocardial injury and diagnosing acute myocardial infarction when a rise and/or fall pattern is demonstrated with at least one value above the 99th percentile upper reference limit. Natriuretic peptides (BNP, NT‑proBNP) aid in diagnosis and risk stratification for heart failure, while older markers (eg, CK, CK‑MB, myoglobin, LDH) have poorer specificity and are generally of limited utility compared with troponin.

    Definitions and Key Terms

    inv-49: Cardiac biomarkers — biochemical markers released in blood from injured myocardial tissue, measurable after a certain period and useful in diagnosis/risk stratification
    DefinitionCardiac biomarkers are biochemical markers released into blood from injured myocardial tissue and measurable after a period following injury
    Clinical roleUsed for diagnosis and risk stratification in acute (e.g., MI) and chronic (e.g., HF) cardiovascular conditions
    ExamplesCommon acute markers include troponin (I or T) and CK‑MB; emerging markers include ST2 (sST2) for prognostic use
    inv-50: Acute coronary syndromes (ACS) — clinical spectrum from angina to myocardial infarction, categorized by ECG into STEMI and NSTEMI/unstable angina
    DefinitionAcute coronary syndromes (ACS) encompass a spectrum from angina and reversible injury to unstable angina and myocardial infarction
    Policy Summary
    PayerOscar Health
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument timing of symptom onset, troponin assay type, and serial troponin sampling (presentation and repeat 3–6 hours or per assay algorithm) to support medical necessity and claims.
    SourceLink
    On This Page
    Coverage Criteria for Cardiac Biomarker TestingProcedure and Test CodesProvider Responsibilities and Billing GuidanceBackground and Evidence SummaryDefinitions and Key Terms

    Follow assay-specific guidance (NICE/ACC/AHA)

    Natriuretic peptides for prognostic use: BNP and NT-proBNP may identify patients with ACS at increased risk of death, heart failure, and recurrent major adverse cardiovascular events and are useful for prognostic assessment in heart failure.

    ACC/AHA/HFSA guideline supports diagnostic and prognostic use; serial measurement for therapy guidance lacks sufficient evidence

    Analytical performanceManufacturer data from 1,100 samples reported CV <5%, linearity, r^2=0.99
    inv-25: NT-proBNP approximate equivalent — NT-proBNP >900 pm/mL roughly equivalent to BNP >100 pg/mL
    Approximate equivalenceNT-proBNP >900 pm/mL is roughly equivalent to BNP >100 pg/mL
    Clinical useNT-proBNP and BNP aid diagnosis in patients presenting with dyspnea and for prognosis in chronic HF
    Age considerationsOptimal NT-proBNP cutpoints vary by patient age and clinical context
    inv-26: Troponin/CK‑MB decision thresholds — Use 99th percentile of the upper reference limit (or assay‑specific limits; NICE suggests near LOD thresholds for some algorithms)
    Primary thresholdUse the 99th percentile of the upper reference limit (URL) as the decision threshold for troponin and, when used, CK‑MB
    Assay‑specific limitsApply sex-specific or assay-specific 99th percentile URLs where provided by the assay manufacturer or lab validation
    NICE noteNICE additionally suggests using thresholds at or near the assay limit of detection for some early rule‑out algorithms, depending on assay; positive near LOD should not be used to rule‑in NSTEMI
    inv-27: hs-cTn threshold — Use 99th percentile thresholds or thresholds at or near the assay limit of detection; note operational considerations for initial samples near LOD
    Preferred thresholdUse 99th percentile thresholds for high-sensitivity cardiac troponin (hs‑cTn)
    Near‑LOD useNICE recommends thresholds at or near the assay limit of detection for some early rule‑out protocols; an initial sample positive near the LOD should not be used to rule in NSTEMI
    Operational considerationDocument assay type (hs‑cTn vs contemporary) and use serial sampling per guidelines (initial and 30–180 minutes or 3–6 hours as indicated) when interpreting values near LOD
    Billing Rule

    Use listed CPT/HCPCS codes from Section VIII

    The policy lists CPT/HCPCS procedure codes for referenced biomarkers in Section VIII for provider billing reference; providers should use these codes when submitting claims.

    • Codes listed include: 82550, 82552, 82553, 82554, 82725, 83615, 83625, 83874, 83880, 84450, 84484, 84512, 84588, 86140, 86141.
    Prior Authorization

    No PA requirements specified in these sections

    No prior authorization requirements are specified elsewhere in the provided document sections; providers must still ensure services meet authorization and medical necessity per the policy header.

    Note
    Step Therapy

    No step‑therapy requirements stated

    No step therapy rules apply to biomarker testing in the provided excerpts; the policy does not impose sequential treatment/testing prerequisites.

    Step Therapy

    Step therapy not applicable

    Step therapy is not applicable for the biomarkers described; the policy instead references guideline preferences (e.g., hs‑cTn) rather than stepwise testing algorithms.

    Note
    Documentation Required

    Submit accurate documentation and follow coding rules

    The policy requires providers to submit accurate documentation and follow authorization and medical‑necessity rules when billing for biomarker testing; claims may be denied if coding/billing guidelines are not followed.

    Documentation Required

    Document symptom timing, assay type, serial troponins, and 99th‑percentile exceedance

    For troponin testing, document timing of symptom onset, the troponin assay type (high‑sensitivity vs contemporary), and serial sampling results including presentation and repeat samples; indicate whether values exceeded the 99th percentile URL.

    • Document time of symptom onset or time of presentation if onset unclear.
    • Record assay type (hs‑cTn vs contemporary) and each sample time and result.
    • Document whether a rise/fall pattern was present and if any value exceeded the 99th percentile URL.
    Documentation Required

    Record troponin sample times and correlate with ECG/imaging

    Record exact sampling times: obtain an initial troponin sample at assessment and a follow-up per guideline (presentation and 3–6 hours after symptom onset; additional sampling beyond 6 hours if indicated) and document ECG/imaging correlates and any rising/falling pattern.

    • Initial sample at presentation; repeat sample at 3–6 hours after symptom onset.
    • Obtain additional samples beyond 6 hours if initial serial troponins are normal but clinical/ECG concern persists.
    • Include ECG and imaging findings that support interpretation.
    Documentation Required

    Follow guideline sampling intervals for hs‑cTn and validate LDTs

    When using high‑sensitivity troponin assays, obtain an initial sample at assessment and, if multiple samples are taken, a second sample 30 minutes to 3 hours later per NICE and other guideline recommendations; ensure any laboratory‑developed test (LDT) is validated in‑house under CLIA '88.

    • If using hs‑cTn and multiple samples, second sample 30–180 minutes after initial per NICE.
    • Use 99th‑percentile thresholds or thresholds near assay limit of detection as specified by guidelines.
    • Validate LDTs in‑house and follow CLIA '88 high‑complexity test requirements.
    Documentation Required

    Cite supporting guidelines (NICE, ASCP, ACC/AHA) in documentation

    Cited guidelines (e.g., NICE, ASCP, ACC/AHA) support use of high‑sensitivity troponin assays for early rule‑out of NSTEMI and recommend against using CK‑MB or myoglobin to diagnose AMI; include these guideline citations in supporting documentation when relevant.

    • NICE recommends hs‑cTn use and specific sampling/threshold approaches.
    • ASCP recommends using troponin I or T and advises against CK‑MB/myoglobin.
    • ACC/AHA/other joint guidelines endorse cTn (I or T), preferably hs‑cTn, for diagnosis of myocardial injury.
    Denial Risk

    Risk of denial for inadequate documentation or inappropriate outpatient testing

    Claims may be denied if coding/billing guidelines or current reimbursement policies are not followed; tests performed in outpatient settings that cannot perform adequate MI evaluation (e.g., independent labs or physician offices) may not meet criteria and risk denial.

    Denial Risk

    Document rise/fall and 99th‑percentile threshold to support MI diagnosis

    For MI diagnosis, document a rise and/or fall pattern with at least one troponin value above the 99th percentile URL; failure to document serial troponins or the diagnostic threshold may lead to denial of MI‑related testing claims.

    • Ensure serial troponin values and timing are recorded and show rise/fall pattern when diagnosing MI.
    • Record whether any value exceeded the 99th percentile upper reference limit.
    Denial Risk

    Avoid CK‑MB or myoglobin for primary MI diagnosis (denial risk)

    ASCP and other guideline statements recommend against using CK‑MB or myoglobin to diagnose acute MI; reliance on these non‑recommended biomarkers for primary diagnosis may result in claim denial if inconsistent with accepted guidance.

    Note

    Government policies take precedence over this policy

    If this Policy conflicts with any applicable government coverage policy (e.g., LCDs or NCDs), the government policy will take precedence for coverage determinations; providers should check relevant Medicare/Medicaid coverage before submission.

    Note

    Use troponin I or T (hs‑cTn preferred); avoid myoglobin/CK‑MB for AMI diagnosis

    Guidelines recommend using cardiac‑specific troponin I or T (preferably high‑sensitivity assays) for AMI diagnosis and advise against testing for myoglobin or CK‑MB; providers should use recommended troponin assays for primary diagnosis to align with guidance and coverage expectations.

    • Use troponin I or T; hs‑cTn assays are preferred for routine clinical use.
    • Do not use myoglobin or CK‑MB as primary diagnostic tests when troponin is available.
    Note
    ECG categorization
    ACS are subdivided by 12-lead ECG into STEMI (ST‑segment elevation) and NSTEMI/unstable angina (ST‑depression, T‑wave changes, or non‑diagnostic ECG)
    Typical presentationPatients usually present with chest pain and associated signs and symptoms; MI diagnosis includes biomarker rise/fall plus clinical/ECG/imaging evidence
    inv-51: High-sensitivity cardiac troponin (hs-cTn) — Troponin I or T assays with high analytical sensitivity recommended for routine clinical use
    Assay typesHigh‑sensitivity cardiac troponin (hs‑cTn) refers to troponin I or T assays with high analytical sensitivity recommended for routine clinical use
    Clinical usehs‑cTn assays detect myocardial injury earlier and have greater negative predictive value for early rule‑out of NSTEMI
    Diagnostic criterionDiagnosis of acute MI requires a rise/fall pattern with at least one value above the 99th percentile URL when using cTn assays
    inv-52: NT-proBNP / BNP — Natriuretic peptide biomarkers released from the heart that aid diagnosis and prognosis in heart failure and acute dyspnea
    DefinitionBNP and NT‑proBNP are natriuretic peptide biomarkers released from the heart that assist in diagnosis and prognosis of heart failure and acute dyspnea
    Clinical applicationMeasure BNP/NT‑proBNP in patients presenting with dyspnea to support diagnosis or exclusion of HF; used for prognosis in chronic HF
    Equivalence noteNT‑proBNP >900 pm/mL is roughly equivalent to BNP >100 pg/mL
    inv-53: sST2 (soluble ST2) — A soluble isoform of ST2 measured (e.g., Presage Assay) as a prognostic biomarker in chronic heart failure
    DefinitionsST2 (soluble ST2) is a soluble isoform of ST2 measured (e.g., Presage Assay) as a prognostic biomarker in chronic heart failure
    BiologysST2 binds IL‑33 and may block cardioprotective IL‑33/ST2L signaling, with higher sST2 associated with fibrosis and worse outcomes
    Assay examplePresage® ST2 Assay is FDA‑cleared and measures sST2 quantitatively for prognostic assessment in chronic HF
    inv-54: Myocardial infarction (MI) — Acute myocardial infarction: designated when a rising/falling pattern of cardiac troponin is seen and at least one measurement is greater than the 99th percentile
    MI diagnostic criterionMyocardial infarction is designated when there is a rising and/or falling pattern of cardiac troponin with at least one value >99th percentile URL
    ContextMI diagnosis also requires clinical symptoms, ECG changes, or imaging evidence consistent with myocardial ischemia/infarction per universal definitions
    Temporal patternCardiac biomarkers rise and fall over time after MI; serial sampling is required to demonstrate dynamic change
    inv-55: Natriuretic peptides — BNP/NT‑proBNP: natriuretic peptide biomarkers used to support diagnosis/exclusion of heart failure and to establish prognosis or disease severity
    DefinitionNatriuretic peptides (BNP/NT‑proBNP) support diagnosis or exclusion of heart failure and provide prognostic information about disease severity
    Use in acute careRapid measurement can help establish or exclude HF in patients presenting with dyspnea
    Prognostic roleMeasurements on admission or predischarge can assist in prognosis for acutely decompensated HF and chronic HF severity assessment
    inv-56: High-sensitivity cardiac troponin (hs-cTn) — Cardiac troponin assays with higher sensitivity and negative predictive value preferred for early detection
    Preferred assaysHigh‑sensitivity cardiac troponin assays are preferred due to greater sensitivity and negative predictive value for early detection
    Operational benefiths‑cTn shortens the time from symptom onset to detection versus conventional assays, enabling earlier rule‑in/rule‑out
    Sampling guidanceInitial and appropriately timed serial samples are recommended when using hs‑cTn for suspected ACS
    inv-57: Laboratory-developed test (LDT) — A test created and validated by a laboratory and regulated by CMS as a high-complexity test under CLIA '88; not necessarily FDA-cleared or approved
    DefinitionLaboratory‑developed test (LDT): a test developed and validated by a laboratory and regulated by CMS as high‑complexity under CLIA '88; not necessarily FDA‑cleared
    Regulatory noteLDTs are not approved/cleared by the FDA but are regulated under CLIA by CMS for clinical use
    Validation requirementLDTs must be validated and performed in‑house by the providing laboratory
    inv-58: Troponin I or T — Cardiac-specific biomarkers recommended by professional societies for diagnosing acute myocardial infarction; high-sensitivity assays are preferred
    RecommendationTroponin I or T are the cardiac‑specific biomarkers recommended by professional societies for diagnosing acute MI; high‑sensitivity assays are preferred
    Specificity noteCardiac troponins have high specificity for cardiac tissue compared with older biomarkers
    Use in guidelinesUniversal and society definitions place troponin rise/fall with >99th percentile as central to MI diagnosis
    inv-59: Myoglobin and CK‑MB — Older biomarkers that professional guidance recommends against using for the diagnosis of acute myocardial infarction in favor of troponins
    GuidanceMyoglobin and CK‑MB are older biomarkers; professional guidance (e.g., ASCP) recommends against their routine use for AMI diagnosis when troponin is available
    CK‑MB exceptionCK‑MB may be used only as an alternative when troponin assays are unavailable
    Risk of nonrecommendationReliance on these nonpreferred biomarkers may be inconsistent with accepted guidance and risk denial per policy